RLBP1 and Retinal atrophy: Three patients in the higher AAV8-RLBP1 dose cohorts (1 in C3 and 2 in C4) developed subretinal pigmented deposits with secondary retinal atrophy adjacent to the retinotomy site that were considered study drug-related.